News and Trends 8 Jan 2018 This British Liquid Biopsy Could Save Us $5000 per Prostate Cancer Patient ANGLE’s liquid biopsy technology measures the expression of an important prostate cancer biomarker, helping to identify the best treatment for different groups of patients. ANGLE is a world leader in the development of liquid biopsies – a technique for the early detection of cancer, which doesn’t require invasive tissue samples. The biotech published results in […] January 8, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2018 This Skin Patch Could Slow the Rate of Antibiotic Resistance Researchers have developed a skin patch that delivers drugs directly into the blood, avoiding the gut which is a breeding ground for antibiotic resistance. Researchers at Queen’s University Belfast are developing a skin patch to deliver drugs through the skin and directly into the bloodstream via thousands of ‘microneedles’. The technology is being tested as a […] January 8, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 8 Jan 2018 Meet the Swiss CEO Pulling Out All the Stops Against Alzheimer’s Disease Efforts to treat Alzheimer’s Disease have been hit with failure after failure in the last year or so. Andrea Pfeifer, co-founder and CEO of AC Immune, told me about how her company hopes to pull off a win. Andrea Pfeifer started out as toxicologist in oncology before she moved into entrepreneurship. She left Germany after […] January 8, 2018 - 8 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 6 Jan 2018 A Self-Portrait of the Microbes that Live on our Skin Is a portrait fully complete without portraying the millions of bacteria that live on our skin? Mellissa Fisher makes them the focus of her self-portraits. British artist Mellissa Fisher creates quite unique portraits. The material for her face sculptures is agar rich in nutrients, the same one that scientists use to grow bacteria and fungi […] January 6, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jan 2018 Takeda Starts the Year Bidding for a Belgian Stem Cell Therapy Biotech Takeda has offered to acquire TiGenix subject to the upcoming European approval of its lead stem cell therapy for Crohn’s disease, Cx601. Short of two years after partnering with TiGenix for the development of a stem cell therapy, Takeda has offered to buy the remaining shares of the company in Euronext Brussels and the Nasdaq […] January 5, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 4 Jan 2018 Belgian Biotech Hits ‘Fast Forward’ on Multiple Sclerosis Therapies Rewind Therapeutics has received a boost in the development of its multiple sclerosis therapies, raising a €15.2M Series A fundraising round. Rewind Therapeutics is a young Belgian biotech, which was co-founded by CD3 and Axxam, based in Leuven, Belgium, and Milan, Italy, respectively. Today, the biotech announced that it has completed a €15.2M Series A financing […] January 4, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jan 2018 Boehringer Ingelheim Doubles its Venture Fund for Exciting Biotech Boehringer Ingelheim has committed to continue helping young companies grow by doubling the size of its venture fund to €250M, which will allow it to expand its focus. Boehringer Ingelheim is a big pharma hoping to drive the development of new and effective medicines. Today, the company announced that it has more than doubled the size of […] January 4, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jan 2018 German Biotech Raises Record $270M Series A for Individualized Cancer Therapies BioNTech will dedicate its huge fundraising to develop personalized cancer immunotherapies using CAR-T, TCR and mRNA technologies. BioNTech is kicking off the new year with great news. The company has closed its Series A with $270M (€225M) — a record amount in Germany for such an early funding round. The fundraising was led by the […] January 4, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jan 2018 Enterome Brings in a €32M Series D for its Microbiome-Based Therapies Enterome will use the money to progress two of its leading microbiome programs for the treatment of Crohn’s disease and an aggressive form of brain cancer. Enterome is a pioneer in the exciting field of microbiome-based therapies for diseases like inflammatory bowel diseases and cancer. This morning, the company has announced that it has raised €32M in […] January 4, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jan 2018 Swedish Biotech Pockets $6M as its Cancer Antibody Heads for the Clinic Alligator Bioscience will receive milestone payments from its partner, Janssen, following the announcement of a combination trial using its cancer antibody. Alligator develops antibodies to fight cancer, and today it has announced that it will receive $6M (€5M) in milestone payments from Janssen. This was triggered by the announcement of a combination trial for its candidate, ADC-1013, which […] January 4, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 4 Jan 2018 A Crash Course in the Basics of Finance in Biotechnology Getting your head around intricate biotech research and technology can be difficult enough, without having to contend with financial figures and jargon. With news coming out thick and fast, you might be switching from the first market approval of a CAR-T therapy to the latest strategy to protect crops from pests to a new anti-Parkinson’s […] January 4, 2018 - 5 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jan 2018 Swiss Biotech Gets $339M to Boost the Development of Drug Addiction Therapies Addex Therapeutics, which develops drugs for neurological disorders, has signed an agreement with Indivior to propel its drug addiction pipeline forward. Addex, a top biotech from Geneva, develops small molecules for the treatment of neurological disorders. Today, the company has announced that a collaboration worth up to $339M (€282M) has been signed with Indivior that will focus on progressing […] January 3, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email